Dezember 2011: HCV – new drugs, new chances and challenges in treatment and diagnostics

December 8, 2011
University Hospital Zurich, Rämistrasse 100, 8091 Zürich
Hörsaal West, 14h-19h

Dear colleagues,

The new drugs for the treatment of Hepatitis C Virus infection will bring new chances but also challenges for treatment and diagnostics. To obtain an update on evolving new drugs against HCV, their resistance patterns and the ensuing consequences for treatment and diagnostics we will hold a Mini-Symposium on Dec 8, 2011 at the University Hospital Zurich.The program and further details on the symposium can be downloaded from our website http://www.virology.uzh.ch/newsd_en.html.

We hope you find this topic interesting and look forward to see you in December.

Sincerely,

Alexandra Trkola
On behalf of the program committee

Program committee

Alexandra TrkolaInstitute of Medical Virology, University of Zurich
Huldrych GünthardDivision of Infectious Diseases, University Hospital Zurich
Jürg BöniInstitute of Medical Virology, University of Zurich
Andri RauchDivision of Infectious Diseases, Inselspital Bern
Beat MüllhauptDivision of Gastroenterology and Hepatology, University Hospital Zurich

HCV – new drugs, new chances and challenges in treatment and diagnostics

December 8, 2011
University Hospital Zurich, Rämistrasse 100, 8091 Zürich
Hörsaal West, 14h-19h

Program:
Admission:There is no admission fee.
Registration:Registration is required. Please send an email to wiget.monika@virology.uzh.ch to register for the symposium.
Lodging and travel:We kindly ask participants to organize travel and accommodation individually.
Credits:This symposium is recognized with 4 CME credits by the FAMH, Microbiology, the Swiss Society of Gastroenterology and the Swiss Society of Infectious Diseases.

Speakers

Stefan ZeuzemJohann Wolfgang Goethe-Universität, FrankfurtNew HCV therapies
David WylesUniversity of California,
San Diego
New drugs and resistance
Karin MetznerUniversity Hospital ZurichResistance testing: Lessons from HIV, Options for HCV
Stephane ChevaliezUniversité Paris-Est CréteilHow to use virological tools for the optimal management of chronic hepatitis C
Markus HeimUniversität BaselThe future of interferon therapy

We gratefully acknowledge the main sponsors of this symposium:

Roche Diagnostics (Schweiz) AG
Roche Pharma (Schweiz) AG
Merck Sharp&Dohme-Cibret AG
Janssen-Cilag AG
And a generous contribution by Abbott AG